Metagenomi Therapeutics, Inc. (MGX) is an in vivo genome editing company headquartered in Emeryville, California, focused on developing curative genetic medicines. The company was founded in 2016 and completed its initial public offering in February 2024 at $15.00 per share. It builds a proprietary, metagenomics-derived toolbox of editing tools, including CRISPR nucleases, base editors, and large-gene integration systems, to correct genetic mutations across the human genome.
The company's lead wholly owned program, MGX-001, is a one-time gene-editing treatment for hemophilia A designed to insert a Factor VIII DNA cassette into the albumin gene, aiming to provide durable protection from bleeding events and joint damage. Metagenomi also maintains a collaboration with Ionis Pharmaceuticals (IONS) across several programs. As a pre-commercial biotech with no approved products, MGX is closely followed for its clinical milestones, cash position, and partnership activity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, MGX has declined approximately 17%, falling from a closing price of about $0.86 in mid-October to near $0.71. The move accelerated as the stock broke decisively below the $1.00 level, a threshold that carries significance for Nasdaq listing requirements.
The quarterly picture is even steeper. Three months earlier, MGX closed around $1.23 in mid-August, meaning the stock has lost roughly 42% over the quarter. The shares reached an intraday 52-week low of $0.60 in early November, far below their 52-week high near $3.95. This sustained slide reflects persistent selling pressure in a thinly traded, low-float micro-cap name rather than a single sharp event.
Several factors combined to pressure MGX over the past month. First, the stock slipped below the $1.00 level in early-to-mid October and has struggled to reclaim it, raising concerns about Nasdaq minimum-bid compliance and the possibility of a reverse stock split or dilutive financing to address it. Micro-cap biotech names trading near their cash value are especially sensitive to these balance-sheet concerns.
Second, third-quarter results reported in early November showed a net loss of $21.13 million, slightly wider than the prior-year period, with nine-month losses of $71.67 million. Collaboration revenue continues to wind down as legacy partnership programs conclude, leaving the company dependent on its cash reserves, which stood at $120.7 million as of June 30, 2026.
Notably, the negative price action persisted even after positive news: on the same day as earnings, the company announced FDA clearance of its IND application for MGX-001 and plans to begin a global clinical trial in the first half of 2027, with initial data expected in the second half of that year. The muted market response underscores investor caution toward a program that remains preclinical, combined with limited trading liquidity that amplifies day-to-day volatility. From what I see, this disconnect is worth monitoring closely.
The quarterly decline extends a longer-running repricing of the stock. Metagenomi underwent a restructuring in November 2025 that cut roughly a quarter of its workforce, and its chief executive departed, with Jian Irish assuming the role. That transition followed the 2024 wind-down of its collaboration with Moderna, which significantly reduced partnership revenue.
Over the past several months, the market has increasingly priced MGX relative to its cash and near-term funding needs rather than its long-term pipeline potential. With no product revenue, a cash burn in the tens of millions of dollars per quarter, and a lead candidate still years from commercialization, the shares have drifted lower despite a consensus "Strong Buy" rating and an average analyst price target near $7 from five analysts. The disconnect between analyst targets and the market price highlights the speculative nature of the valuation at this stage.
Looking ahead, the key catalysts for MGX center on clinical execution and capital. Investors are likely to monitor the planned initiation of the MGX-001 global clinical trial in the first half of 2027 and the initial clinical data anticipated in the second half of the year. Funding is equally critical: the company has guided that its cash supports operations into the fourth quarter of 2027, but any financing decisions, share issuance, or reverse-split action tied to Nasdaq compliance could materially affect the stock.
Additional factors to watch include updates on the Ionis collaboration, analyst price-target revisions as the clinical timeline firms up, and broader biotech-sector sentiment. As always, these developments carry risk, and the stock's behavior will depend on whether the company can translate its preclinical promise into clinical data before its cash runway narrows. I’m watching this closely as the timeline firms up.
In my own analysis of names like MGX, I’ve turned to Tickeron’s AI Trading Bots to test rules-based strategies across different timeframes. The platform offers a range of bots that monitor market signals and can help surface patterns I might otherwise overlook, providing an additional layer of data alongside traditional fundamental review. It’s been a practical way to cross-check sentiment in volatile micro-cap names without replacing core due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MGX declined for three days, in 158 of 180 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for MGX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MGX's RSI Oscillator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 26 of 30 cases where MGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for MGX just turned positive on October 29, 2026. Looking at past instances where MGX's MACD turned positive, the stock continued to rise in 18 of 22 cases over the following month. The odds of a continued upward trend are 82%.
Following a +4.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGX advanced for three days, in 88 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
MGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (3.195) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology